Dr Reddy’s Enters OTC Eyecare Space
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
You may also be interested in...
Abbvie business starts sales of Lastacaft (alcaftadine solution/0.25%) eye drops, licensed from innovator Vistakon Pharmaceuticals, approved through an sNDA. Full switch removes Lastacaft from Rx sales in US.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.